Ocular Therapeutix Reports Superiority Data for AXPAXLI in Wet AMD Phase 3 Trial
Ocular Therapeutix announced positive topline results from the SOL-1 Phase 3 superiority trial of AXPAXLI for wet age-related macular degeneration, meeting its primary endpoint with statistically significant improvements in vision outcomes compared to aflibercept.